Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Tuberous Sclerosis 6 Seizures 5 Marijuana Abuse 3 Lennox Gastaut Syndrome 3 Epilepsies, Myoclonic 3 Colonic Neoplasms 3 Breast Neoplasms 3 Sturge-Weber Syndrome 2 Neoplasms 2 Nausea 2 Glioblastoma 2 Anxiety Disorders 2 Vomiting 1 Tuberous Sclerosis 2 1 Tuberous Sclerosis 1 1 Spasms, Infantile 1 Solid Tumor 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Parasomnias 1 Pancreatic Neoplasms 1 Pain 1 Multiple Myeloma 1 Liver Neoplasms 1 Liver Cirrhosis 1 Gallbladder Neoplasms 1 Epilepsy 1 Dysgeusia 1 Drug Resistant Epilepsy 1 Colorectal Neoplasms 1

Interventions

Morphine 16 Oxycodone 14 Fentanyl 10 Methadone 7 nabiximols 5 Lidocaine 5 Acetaminophen 5 resiniferatoxin 4 Hydromorphone 4 Ethanol 4 Acupuncture Therapy 4 Transcutaneous Electric Nerve Stimulation 3 Buprenorphine 3 Transcranial Direct Current Stimulation 2 Tapentadol 2 Surveys and Questionnaires 2 Standard of Care 2 Sodium Bicarbonate 2 Radiosurgery 2 Radiofrequency Ablation 2 Pharmaceutical Services 2 Naloxone 2 Ketamine 2 Electroacupuncture 2 Dronabinol 2 Control Groups 2 Analgesics, Opioid 2 6'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine 2 tanezumab 1 rofecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Cancer Pain × Cannabidiol × Clear all

NCT06533657 2026-04-21

UTOPIA-1

ZYUS Life Sciences Inc.

Phase 2 Completed

Cancer Pain

Data powered by HemOnc (CC BY 4.0) Colophon ⚡